Π‘ΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° C
ΠΠ»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ²ΡΡ ΡΠ°ΡΡΡ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ΄ΠΈΠΌΠ΅ΡΠ½ΡΠ΅ Π½Π΅ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΡΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΠΎΠ±ΠΎΠ»ΠΎΡΠ΅ΡΠ½ΡΡ Π³Π»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ² Π1 ΠΈ Π2. ΠΡΠ½ΠΎΠ²Π½ΡΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ Π΄Π»Ρ ΠΠΠ‘ ΡΡΠΈΡΠ°Π΅ΡΡΡ CD81, ΠΊΠΎΡΠΎΡΡΠΉ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ Ρ Π±Π΅Π»ΠΊΠΎΠΌ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π2. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ»ΠΈΠΌΠΈΠ½Π°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π²ΡΡΠ°Π±ΠΎΡΠΊΠ° Π°Π½ΡΠΈ-Π2 Π°Π½ΡΠΈΡΠ΅Π», Π½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ ΠΠΠ‘ Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ. Π Π±Π΅Π»ΠΊΠ΅ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π2 ΠΠΠ‘ Π½Π°ΠΉΠ΄Π΅Π½Ρ ΠΊΠ°ΠΊ Π»ΠΈΠ½Π΅ΠΉΠ½ΡΠ΅, ΡΠ°ΠΊ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- ΠΠ»Π°Π²Π° 1. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΡ
Π΄Π°Π½Π½ΡΡ
- 1. 1. Π‘ΡΡΠΎΠ΅Π½ΠΈΠ΅ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (ΠΠΠ‘)
- 1. 2. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΠΠ‘
- 1. 2. 1. ΠΠ»Π΅ΡΠΎΡΠ½Π°Ρ ΠΊΡΠ»ΡΡΡΡΠ° ΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
- 1. 2. 2. ΠΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π³Π΅Π½ΠΎΠΌΠ° ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡ
- 1. 2. 3. Π‘ΡΡΡΠΊΡΡΡΠ° Π±Π΅Π»ΠΊΠΎΠ² ΠΠΠ‘ ΠΈ ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ
- 1. 2. 4. Π¦ΠΈΠΊΠ» ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΠΠ‘
- 1. 2. 5. ΠΠ°ΡΠΎΠ³Π΅Π½Π΅Π·, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘
- 1. 3. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π±Π΅Π»ΠΊΠ° Π2 ΠΠΠ‘ Ρ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡΡ
- 1. 3. 1. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π±Π΅Π»ΠΊΠ° Π
- 1. 3. 2. Π‘ΡΡΡΠΊΡΡΡΠ° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD
- 1. 3. 3. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π±Π΅Π»ΠΊΠ° Π2 Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ CD
- 1. 3. 4. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Π±Π΅Π»ΠΊΠ° Π2 Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ°ΠΌΠΈ Π΄Π»Ρ ΠΠΠ‘
- 1. 4. Π‘ΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π±Π΅Π»ΠΊΠ° NS3 ΠΠΠ‘
- 1. 4. 1. Π‘Π΅ΡΠΈΠ½ΠΎΠ²Π°Ρ npOTea3aNS3 ΠΈ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ Π΅Π΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ
- 1. 4. 2. Π‘ΡΡΡΠΊΡΡΡΠ° ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ Ρ Π΅Π»ΠΈΠΊΠ°Π·Ρ NS
- 1. 5. Π ΠΎΠ»Ρ Π±Π΅Π»ΠΊΠΎΠ² ΠΠΠ‘ Π² Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΠΎΠΌ ΠΈ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ΅
- ΠΠ»Π°Π²Π° 2. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ
- 2. 1. ΠΠ»Π΅ΡΠΊΠΈ, ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Ρ, ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅
- 2. 2. ΠΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2(384−661) ΠΠΠ‘ Π΄Π»Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π² E. col
- 2. 3. ΠΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° NS3 ΠΠΠ‘ Π΄Π»Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π² E. col
- 2. 4. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² Π2, NS3 ΠΈ CD81 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ E. col
- 2. 5. ΠΡΠΈΡΡΠΊΠ° ΡΠ΅Π»Π΅Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ
- 2. 6. ΠΡΠΈΡΡΠΊΠ° ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π2 Π½Π° Ni-NTA ΡΠΌΠΎΠ»Π΅
- 2. 7. ΠΡΠΈΡΡΠΊΠ° ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD81 Π½Π° Π³Π»ΡΡΠ°ΡΠΈΠΎΠ½-ΡΠ΅ΡΠ°ΡΠΎΠ·Π΅ 4Π
- 2. 8. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2 Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ CD
- 2. 9. Π’Π²Π΅ΡΠ΄ΠΎΡΠ°Π·Π½ΡΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· (ELISA)
- 2. 10. ΠΠΌΠΌΡΠ½ΠΎΠ±Π»ΠΎΡΡΠΈΠ½Π³
- ΠΠ»Π°Π²Π° 3. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅
- 3. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2 (384−661) ΠΠΠ‘
- 3. 1. 1. ΠΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2 (384−661) ΠΠΠ‘
- 3. 1. 2. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π2(384−661) Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ E. coli BL21[DE3]
- 3. 1. 3. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈ ΠΎΡΠΈΡΡΠΊΠ° Π±Π΅Π»ΠΊΠ° Π2 Π½Π° Ni-NTA ΡΠΌΠΎΠ»Π΅
- 3. 1. 4. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2(384−661) Ρ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ
- 3. 1. 5. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ, Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈ ΠΎΡΠΈΡΡΠΊΠ° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD
- 3. 1. 6. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2(384−661) Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ CD
- 3. 2. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° NS3 ΠΠΠ‘. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π΅Π³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ Ρ Π°Π½ΡΠΈ-ΠΠΠ‘ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°Ρ
ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΠΠ‘
- 3. 2. 1. ΠΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° NS3 ΠΠΠ‘
- 3. 2. 2. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΠΈ ΠΎΡΠΈΡΡΠΊΠ° ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° NS3 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ Π. coli Π-15 [REP4]
- 3. 2. 3. ΠΠ·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° NS3 Ρ ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°ΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘
- 3. 3. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΠΎΠΌΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠΌΡ Π±Π΅Π»ΠΊΡ NS
- 3. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π2 (384−661) ΠΠΠ‘
- ΠΡΠ²ΠΎΠ΄Ρ
Π‘ΡΡΡΠΊΡΡΡΠ½ΡΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° C (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ (ΠΠΠ‘) ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π±ΠΎΠ»Π΅Π΅ 170 ΠΌΠΈΠ»Π»ΠΈΠΎΠ½ΠΎΠ² ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ Π²ΠΎ Π²ΡΠ΅ΠΌ ΠΌΠΈΡΠ΅. ΠΠΠ‘ ΠΈΠ·Π²Π΅ΡΡΠ΅Π½ ΠΊΠ°ΠΊ ΠΎΠ΄ΠΈΠ½ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ², Π²ΡΠ·ΡΠ²Π°ΡΡΠΈΡ ΠΎΡΡΡΡΠ΅ ΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π³Π΅ΠΏΠ°ΡΠΈΡΡ Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ ΡΠΈΠΌΠΏΠ°Π½Π·Π΅. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ ΠΏΡΠΈΠ±Π»ΠΈΠ·ΠΈΡΠ΅Π»ΡΠ½ΠΎ Π² 50−80% ΡΠ»ΡΡΠ°Π΅Π² ΠΈ Π² ΠΊΠΎΠ½ΡΠ΅ ΠΊΠΎΠ½ΡΠΎΠ² ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ 20−50% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊ ΡΠΈΡΡΠΎΠ·Ρ ΠΈ ΠΏΡΠΈΠ±Π»ΠΈΠ·ΠΈΡΠ΅Π»ΡΠ½ΠΎ 5% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² — ΠΊ Π³Π΅ΠΏΠ°ΡΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ΅ [Gardner et al., 2003; Pawlotsky, 2004; Panther, 2004].
ΠΠ»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ²ΡΡ ΡΠ°ΡΡΡ Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ΄ΠΈΠΌΠ΅ΡΠ½ΡΠ΅ Π½Π΅ΠΊΠΎΠ²Π°Π»Π΅Π½ΡΠ½ΡΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΡ ΠΎΠ±ΠΎΠ»ΠΎΡΠ΅ΡΠ½ΡΡ Π³Π»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ² Π1 ΠΈ Π2. ΠΡΠ½ΠΎΠ²Π½ΡΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ Π΄Π»Ρ ΠΠΠ‘ ΡΡΠΈΡΠ°Π΅ΡΡΡ CD81, ΠΊΠΎΡΠΎΡΡΠΉ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ Ρ Π±Π΅Π»ΠΊΠΎΠΌ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π2. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ»ΠΈΠΌΠΈΠ½Π°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ Π²ΡΡΠ°Π±ΠΎΡΠΊΠ° Π°Π½ΡΠΈ-Π2 Π°Π½ΡΠΈΡΠ΅Π», Π½Π΅ΠΉΡΡΠ°Π»ΠΈΠ·ΡΡΡΠΈΡ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ ΠΠΠ‘ Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ. Π Π±Π΅Π»ΠΊΠ΅ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ Π2 ΠΠΠ‘ Π½Π°ΠΉΠ΄Π΅Π½Ρ ΠΊΠ°ΠΊ Π»ΠΈΠ½Π΅ΠΉΠ½ΡΠ΅, ΡΠ°ΠΊ ΠΈ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠΏΠΈΡΠΎΠΏΡ. [Clayton et al., 2002]. ΠΠΠ‘ Π²ΡΡΠΎΠΊΠΎ ΠΈΠ·ΠΌΠ΅Π½ΡΠΈΠ², ΡΡΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΡΡΡΠ΄Π½ΠΎΡΡΠΈ Π² Π΅Π³ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ [Shaw, 2003]. ΠΠΎΡΡΠΎΠΌΡ ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ Π²ΡΠ΅ ΠΈΠ·ΠΎΠ»ΡΡΡ Π²ΠΈΡΡΡΠ°. ΠΠΎΡΠΊΠΎΠ»ΡΠΊΡ ΠΈΠ·-Π·Π° Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΌΡΡΠ°ΡΠΈΠΈ ΠΠΠ‘ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎ ΠΏΠΎΡΠ²Π»ΡΡΡΡΡ Π½ΠΎΠ²ΡΠ΅ Π²ΠΈΡΡΡΠ½ΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ, Π³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅Ρ ΠΊ ΡΡΠΈΠΌ Π²ΠΈΡΡΡΠ½ΡΠΌ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡΠΌ ΡΠΎΡ ΡΠ°Π½ΡΠ΅ΡΡΡ Π»ΠΈΡΡ Π΄ΠΎ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ΅ΡΠΎΠ²Π°ΡΠΈΠ°Π½ΡΠ° Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ, ΡΡΠΎ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ°ΡΡΡΠΈΡΡΠ²Π°ΡΡ Π½Π° Π΄ΠΎΠ»Π³ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΉ ΡΡΡΠ΅ΠΊΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΡΠΎΠ»ΡΠΊΠΎ ΠΎΠ΄Π½ΠΈΠΌ Π±Π΅Π»ΠΊΠΎΠΌ [Berzovsky et al., 2004].
Π ΠΎΡΡΡΠΎΠΉ ΡΠ°Π·Π΅ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π½Π΅ΡΡΡΡΠΊΡΡΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΡΡ ΠΏΠΎΠ·ΠΆΠ΅, ΡΠ΅ΠΌ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΡΡΡΡΠΊΡΡΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ. ΠΠ΅Π»ΠΎΠΊ NS3 ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΠΊ Π½Π΅ΡΡΡΡΠΊΡΡΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ ΠΠΠ‘ ΠΈ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΠΌΠΈ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΡΠ½ΠΊΡΠΈΡΠΌΠΈ. ΠΡΡΠΎΠΊΠΈΠ΅ ΡΠΈΡΡΡ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ NS3 Π² ΠΎΡΡΡΠΎΠΉ ΡΠ°Π·Π΅ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ ΠΊΠ°ΠΊ ΠΌΠ°ΡΠΊΠ΅Ρ Ρ ΡΠΎΠ½ΠΈΠ·Π°ΡΠΈΠΈ [Jovilet-Reynaud et al., 2004].
Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² ΠΠΠ‘ ΠΈΠΌΠ΅Π΅Ρ ΠΎΠ³ΡΠΎΠΌΠ½ΠΎΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅. ΠΠ°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π°Π½Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² Π²Π°ΠΆΠ½Ρ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π΄Π»Ρ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ΅ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° Π½Π° Π²ΠΈΡΡΡΡ ΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ Π³Π΅Π½ΠΎΡΠΈΠΏΠ°ΠΌ, Π½ΠΎ ΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ.
Π¦Π΅Π»Ρ ΠΈ Π·Π°Π΄Π°ΡΠΈ ΡΠ°Π±ΠΎΡΡ. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘.
ΠΠ»Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΠΎΠΉ ΡΠ΅Π»ΠΈ Π±ΡΠ»ΠΈ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π·Π°Π΄Π°ΡΠΈ:
1. ΠΠΎΠ»ΡΡΠΈΡΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΡΠΉ Π±Π΅Π»ΠΎΠΊ Π2 Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘, ΠΈΠ·ΡΡΠΈΡΡ Π΅Π³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ CD81.
2. ΠΠΎΠ»ΡΡΠΈΡΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΡΠΉ Π±Π΅Π»ΠΎΠΊ NS3 Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘, ΠΈΠ·ΡΡΠΈΡΡ Π΅Π³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ Ρ Π°Π½ΡΠΈ-ΠΠΠ‘ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°Ρ ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΠΠ‘.
3. ΠΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅, ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΌ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΌ Π±Π΅Π»ΠΊΠ°ΠΌ.
ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π° ΠΈ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅Π½Π½ΠΎΡΡΡ ΡΠ°Π±ΠΎΡΡ.
ΠΠΎΠ»ΡΡΠ΅Π½Ρ ΠΈ ΠΎΡ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Ρ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ Π2 ΠΈ NS3 ΠΠΠ‘, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π² E.coli. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π½Π΅Π³Π»ΠΈΠΊΠΎΠ·ΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠΎΡΠΌΠ° Π2 ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΡΠ΅Ρ ΠΊΠ°ΠΊ Ρ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΌΠΈ ΠΏΡΠΎΡΠΈΠ² ΡΡΠΊΠ°ΡΠΈΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π° Π2, ΡΠ°ΠΊ ΠΈ Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΈΠΌ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠΌ CD81. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΌΠ΅ΡΠΎΠ΄ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π½Π΅Π³Π»ΠΈΠΊΠΎΠ·ΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π2 Π² Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π΅Π½ ΠΈ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅Π½, ΡΠ΅ΠΌ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΊΠ°ΡΠΈΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π»ΠΈΠΊΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π° Π2. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π½Π°ΠΌΠΈ ΠΏΠΎΠ»ΡΡΠ΅Π½ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΡΠΉ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ Π±Π΅Π»ΠΎΠΊ NS3 ΠΠΠ‘ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ Π΅Π³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ Π°Π½ΡΠΈ-NS3 Π°Π½ΡΠΈΡΠ΅Π» Π² ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌΠ°Ρ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘.
Π²ΡΠ²ΠΎΠ΄Ρ.
1. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠ°Π½Π΅Π»ΠΈ Π°Π½ΡΠΈ-Π2 ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΡΠ΅Π» ΠΈ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° CD81 ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΉ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ Π±Π΅Π»ΠΎΠΊ Π2 Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ Π°ΠΊΡΠΈΠ²Π½ΡΠΌ.
2. ΠΠΎΠ»ΡΡΠ΅Π½ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ ΠΏΠΎΠ»Π½ΠΎΡΠ°Π·ΠΌΠ΅ΡΠ½ΡΠΉ Π±Π΅Π»ΠΎΠΊ NS3 ΠΠΠ‘. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ NS3 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘.
3. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ Π2 ΠΈ NS3 ΠΈΠΌΠ΅ΡΡ Π²Π°ΠΆΠ½ΠΎΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π² ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌΠ°Ρ Π΄Π»Ρ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ aHTH-NS3 Π°Π½ΡΠΈΡΠ΅Π» Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ°Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π‘.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠΎΡ ΠΎΠ½ΠΎΠ² Π.Π., ΠΠΎΠ²ΠΈΠΊΠΎΠ² Π. Π., Π‘Π°ΠΌΠΎΡ Π²Π°Π»ΠΎΠ² Π. Π., Π¨Π°ΡΠ°Π»ΠΎΠ² Π. Π., ΠΡΠΈΠ»ΠΈΠΏΠΎΠ² Π. Π. // Π‘ΡΡΡΠΊΡΡΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘ // ΠΠΎΠΏΡΠΎΡΡ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, № 1, 2002.
- Π―ΡΡΡΠ΅Π±ΠΎΠ²Π° Π.Π. // ΠΠ΅ΠΏΠ°ΡΠΈΡ Π‘ // ΠΠΎΠ»ΡΡΠΎΠ²ΠΎ, Π‘. 30, 2000.
- Artsaenko O., Tessmann K., Sack M., Haussinger D., Heintges T. // Abrogation of hepatitis Π‘ virus NS3 helicase enzymatic activity by recombinant human antibodies // J. Gen. Virol., v. 84(Pt 9), pp. 2323−2332, 2003.
- Bartenschlager R., Kaul A., Sparasio S. // Replication of the hepatitis Π‘ virus in cell culture // Antiviral. Res., v. 60(2), pp. 91−102, 2003.
- Beard M.R., Abell G., Honda M., Carroll A., Gartland M., Clarke Π., Suzuki K., Lanford R., Sangar D.V., Lemon S.M. // An infectious molecular clone of a Japanese genotype lb hepatitis Π‘ virus // Hepatology, v. 30(1), pp. 316 324, 1999.
- Berzovsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., and Belyakov I.M. // Progress on new vaccine strategies against chronic viral infections // J. Clin. Invest., v. 114, pp. 450−462, 2004.
- Beeck A., Dubuisson J. // Topology of hepatitis Π‘ virus envelope glycoproteins // Rev. Med. Virol., v. 13(4), pp. 233−241, 2003.
- Blight K.J., Kolykhalov A.A., Rice C.M. // Efficient initiation of HCV RNA replication in cell culture // Science., v. 290(5498), pp. 1972−1974, 2000.
- Blight K.J., McKeating J.A., Marcotrigiano J., Rice C.M. // Efficient replication of hepatitis Π‘ virus genotype la RNAs in cell culture // J. Virol., v. 77(5), pp. 3181−3190, 2003.
- Carloni G., Iacovacci S., Sargiacomo M., Ravagnan G., Ponzetto A., Peschle C., Battaglia M. // Susceptibility of human liver cell cultures to hepatitis Π‘ virus infection // Arch. Virol. Suppl., v. 8, pp. 31−39, 1993.
- Carlos M.P., Yamamura Y., Vu Q., Conzen K., Anderson D.E., Torres J.V. // Humoral immunity to immunodominant epitopes of Hepatitis Π‘ vims inindividuals infected with genotypes la or lb // Clin. Immunol., v. 111(1), pp. 22−27, 2004.
- Carrere-Kremer S., Montpellier-Pala C., Cocquerel L., Wychowski C., Penin F., Dubuisson J. // Subcellular localization and topology of the p7 polypeptide of hepatitis Π‘ virus // J. Virol., v. 76(8), pp. 3720−3730, 2002.
- Chen L., Chen P., Fan G., Li L., Liu C. // Localization of hepatitis Π‘ virus core protein in the nucleus of peripheral blood mononuclear cells of hepatitis Π‘ patients // Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi., v. 16(1), pp. 37−39, 2002.
- Clayton R.F., Owsianka A., Aitken J., Graham S., Bhella D., Patel A.H. // Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis Π‘ virus-like particles // J.Virol., v. 76(15), pp. 76 727 682, 2002.
- Cocquerel L., Kuo C.C., Dubuisson J., Levy S. // CD81-dependent binding of hepatitis Π‘ virus E1E2 heterodimers // J. Virol., v. 77(19), pp. 1 067 710 683,2003.
- Diepolder HM. // Prevention and therapy of viral hepatitis // Internist.(Berl). v. 45(2), pp. 197−209,2004.
- Dou X.G., Talekar G., Chang J., Dai X., Li L., Bonafonte M.T., Holloway Π., Fields H.A., Khudyakov Y.E. // Antigenic heterogeneity of the hepatitis Π‘ virus NS5A protein // J. Clin. Microbiol., v. 40(1), pp. 61−67, 2002.
- Drummer H.E., Poumbourios P. // Hepatitis Π‘ virus glycoprotein E2 contains a membrane-protein heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry // J. Biol. Chem., v. 279(29), pp. 30 066−30 072, 2004.
- Drummer H.E., Wilson K.A., and Poumbourios P. // Identification of the Hepatitis Π‘ virus E2 glycoprotein binding site on the large extracellular loop of CD81 // J. Virol., v. 76(21), pp. 11 143−11 147, 2002.
- Duenas-Carrera S. // DNA vaccination against hepatitis Π‘ // Curr. Opin. Mol. Ther., v. 6(2), pp. 146−150, 2004.
- Errington W., Wardell A.D., McDonald S., Goldin R.D., McGarvey M.J. // Subcellular localization of NS3 in HCV-infected hepatocytes // J. Med. Virol., v. 59(4), pp. 456−462, 1999.
- Failla C.M., Pizzi E., De Francesco R., Tramontano A. // Redesigning the substrate specificity of the hepatitis Π‘ virus NS3 protease // Fold. Des., v. 1(1), pp. 35−42, 1996.
- Fan Z., Yang Q.R., Twi J.S., Sherker A.H. // Specific in vitro association between the hepatitis Π‘ viral genome and core protein // J. Med. Virol., v. 59(2), pp. 131−134, 1999.
- Farci P., Purcell R.H. // Clinical significance of hepatitis Π‘ virus genotypes and quasispecies // Semin. Liver. Dis., v. 20(1), pp. 103−126, 2000.
- Flint M., Dubuisson J., Maidens C., Harrop R., Guile G. R., Borrow P., and McKeating J. A. // Functional characterization of intracellular and secreted forms of a truncated hepatitis Π‘ virus E2 glycoprotein // J.Virol., v. 74, pp. 702−709, 2000.
- Foy E., Li K., Wang C., Sumpter R. Jr., Ikeda M., Lemon S.M., Gale M. Jr. // Regulation of interferon regulatory factor-3 by the hepatitis Π‘ vims serine protease // Science., v. 300(5622), pp. 1145−1148, 2003.
- Francesco R., Pessi A., Steinkuhler C. // Mechanisms of hepatitis Π‘ virus NS3 proteinase inhibitors // J. Viral. Hepat., v. 6(Suppl 1), pp. 23−30, 1999.
- Frelin L. // Development of vaccines and experimental models for chroniv infections caused by the hepatitis Π‘ virus // Karolinska University Press, Stockholm, Sweden, p. 84, 2004.
- Fried M.W. // Viral factors affecting the outcome of therapy for chronic hepatitis Π‘ // Rev. Gastroenterol. Disord., v. 4(Suppll), pp. 8−13, 2004.
- Gardner J.P., Durso R.J., Arrigale R.R., Donovan G.P., Maddon P.J., Dragic Π’., and Olson W.S. // L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis Π‘ virus // PNAS, v. 100(8), pp. 4498−4503, 2003.
- Germi R., Crance J.M., Garin D., Zarski J.P., Drouet E. // Hepatitic Π‘ virus culture systems // Pathol. Biol (Paris)., v. 49(3), pp. 255−261, 2001.
- Goutagny N., Fatmi A., De Ledinghen V., Penin F., Couzigou P., Inchauspe G., Bain C. // Evidence of viral replication in circulating dendritic cells during hepatitis Π‘ virus infection // J. Infect. Dis., v. 187(12), pp. 19 511 958,2003.
- Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., Walker C.M. // HCV persistence and immune evasion in the absence of memory T cell help // Science., v. 302(5645), pp. 659−662, 2003.
- Howard C.R. // Hepatitis Π‘ vims: clades and properties // J. Gastroenterol. Hepatol., 17 Suppl, pp. 468−470, 2002.
- Howe A.Y., Chase R., Taremi S.S., Risano C., Beyer Π., Malcolm Π., Lau J.Y. // A novel recombinant single-chain hepatitis Π‘ vims NS3-NS4A protein with improved helicase activity // Protein. Sci., v. 8(6), pp. 13 321 341, 1999.
- Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., and McKeating J.A. // Hepatitis Π‘ vims glycoptoteins mediate pH-dependent cell entry of pseudotyped retroviral particles // PNAS, v. 100(12), pp. 72 717 276, 2003.
- Imbert I., Dimitrova M., Kien F., Kieny M.P., Schuster C. // Hepatitis Π‘ vims IRES efficiency is unaffected by the genomic RNA 3'NTR even in thepresence of viral structural or non-structural proteins // J. Gen. Virol., v. 84(Pt6), pp. 1549−1557, 2003.
- Jones I.M., Chan-Fook C. // Receptors for hepatitis Π‘ virus // J. Virol., pp. 10 860−10 861,2000.
- Kato N. // Genome of human hepatitis Π‘ virus (HCV): gene organization, sequence diversity, and variation // Microb. Π‘ΠΎΡΡ. Genomics., v. 5(3), pp. 129−151,2000.
- Keck Z.Y., Sung V.M., Perkins S., Rowe J., Paul S" Liang T.J., Lai M.M., Foung S.K. // Human monoclonal antibody to hepatitis Π‘ virus El glycoprotein that blocks virus attachment and viral infectivity // J. Virol., v. 78(13), pp. 7257−7263, 2004.
- Kien F., Abraham J.D., Schuster C., Kieny M.P. // Analysis of the subcellular localization of hepatitis Π‘ virus E2 glycoprotein in live cells using EGFP fusion proteins // J. Gen. Virol., v. 84(Pt3), pp. 561−566, 2003.
- Kim D.W., Kim J., Gwack Y., Han J.H., and Choe J. // Mutational analysis of the hepatitis Π‘ virus RNA helicase // J. of Virology., v. 71(12), pp. 94 009 409, 1997.
- Kitadokoro K., Bordo D., Galli G., Petracca R., Falugi F., Abrignani S., Grandi G., and Bolognesi M. // CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs // EMBO J., v.20(l), pp. 12−18,2001.
- Kunkel M., Watowich S.J. // Biophysical characterization of hepatitis Π‘ virus core protein: implications for interactions within the virus and host // FEBS Lett., v. 557(1−3), pp. 174−180, 2004.
- Kups J., Wozniakowska-Gesicka T. // Evaluation of specific humoral response to hepatitis Π‘ core antigen in children // Przegl. Lek., v. 60(12), pp. 802−805,2003.
- Kwong A.D., Kim J.L., Rao G., Lipovsek D., Raybuck S.A. // Hepatitis Π‘ vims NS3/NS4A protease // Antiviral. Res., v. 41(1), pp. 67−84, 1999.
- Kwong A.D., Kim J.L., Lin C. // Structure and function of hepatitis Π‘ virus NS3 helicase // Curr. Top. Microbiol. Immunol., v. 242, pp. 171−196, 2000.
- Lam A.M.I., Keeney D., and Frick D.N. // Two novel conserved motifs in the hepatitis Π‘ virus NS3 protein critical for helicase action // J. of Biol. Chem., v. 278(45), pp. 44 514−44 524, 2003.
- Lanford R.E., Bigger C., Basset S., Klimpel G. // The chimpanzee model of hepatitis Π‘ vims infections // ILAR J., v. 42(2), pp. 117−126, 2001.
- Levy S., Nguyen V.Q., Andria M.L., Takahashi S. // Structure and membrane topology of TAPA-1 // J. of Biol.Chem., v. 266, pp.14 597−14 602, 1991.
- Liang T.J., Hoofnagle J.H., Gallin J.I., Fauci A.S. // Hepatitis Π‘ (A volume in the biomedical research reports) // Academic Press, P. 512, 2000.
- Lin C., and Kim J.L. // Structure-based mutagenesis study of hepatitis Π‘ virus NS3 helicase // J. of Virology., v. 73(10), pp. 8798−8807, 1999.
- Marco S.D., Rizzi M., Volpari C., Walsh M.A., Narjes F., Colarusso S., Francesco R.D., Matassa V.G., and Sollazzo M. // Inhibition of the hepatitis Π‘ virus NS¾A protease // J. of Biological Chemistry., v. 275(10), pp. 7152−7157, 2000.
- Martin F., Dimasi N., Volpari C., Perrera C., Di Marco S., Brunetti M., Steinkuhler C., De Francesco R., Sollazzo M. // Design of selective eglin inhibitors of HCV NS3 proteinase // Biochemistry., v. 37(33), pp. 1 145 911 468, 1998.
- Mihm S., Frese M., Meier V., Wietzke-Braun P., Scharf J.G., Bartenschlager R., Ramadori G. // Interferon type I gene expression in chronic hepatitis Π‘ // Lab. Invest., v. 84(9), pp. 1148−1159, 2004.
- Mondelli M.U., Cerino A., Meola A., Nicosia A. // Variability or conservation of hepatitis Π‘ virus hypervariable region 1? Implications for immune responses // J. Biosci., v. 28(3), pp. 287−304, 2003.
- Moriishi K., Matsuura Y. // Mechanisms of hepatitis Π‘ virus infection // Antivir. Chem. Chemother., v. 14(6), pp. 285−297, 2003.
- Nakano I., Fukuoa Y., Katano Y., and Hayakawa I. // Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis Π‘ virus // J. Infection diseases., v. 180, pp. 1328−1333, 1999.
- Nozaki A., Ikeda M., Naganuma A., Nakamura Π’., Inudoh M., Tanaka K., Kato N. // Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis Π‘ virus E2 envelope protein // J. Biol. Chem., v. 278(12), pp. 10 162−10 173,2003.
- Panther E., Spangenberg H.C., Neumann-Haefelin C., Rosier K., Blum H.E., von Weizsacker F., Thimme R. // The role of the virus specific T-cell response in acute and chronic HBV and HCV infection // Z. Gastroenterol., v. 42(1), pp. 39−46, 2004.
- Petit Π-A., Jolivet-Reynaud Π‘., Peronnet E., Michal Y., and Trepo C. // Mapping of conformational epitope shared between El and E2 jn the serum-derived human hepatitis Π‘ virus envelope // JBC., p. 33., 2003.
- Pawlotsky J.M. // Pathophysiology of hepatitis Π‘ virus infection and related liver disease // Trends. Microbiol., v. 12(2), pp. 96−102, 2004.
- Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. // Structural biology of hepatitis Π‘ virus // Hepatology, v. 39(1), pp. 5−19, 2004.
- Pietschmann Π’., Bartenschlager R. // Tissue culture and animal models for hepatitis Π‘ virus // Clin. Liver Dis., v. 7(1), pp. 23−43, 2003.
- Pohlmann S., Zhang J., Baribaud F., Chen Z., Leslie G.J., Lin G., Granelli-Piperno A., Doms R.W., Rice C.M., McKeating J.A. // Hepatitis Π‘ virus glycoproteins interact with DC-SIGN and DC-SIGNR // J. Virol., v. 77(7), pp. 4070−4080, 2003.
- Randall G., Grakoui A., and Rice C.M. // Clearance of replicating hepatitis Π‘ virus replicon RNAs in cell culture by small interfering RNAs // PNAS, v. 100(1), pp. 235−240, 2003.
- Seder R.A., Hill A.V. // Vaccines against intracellular infections requiring cellular immunity // Nature., v. 406(6797), pp. 793−798, 2000.
- Serebrov V., and Pyle A.M. // Periodic cycles of RNA unwinding and pausing by hepatitis Π‘ virus NS3 helicase // NATURE., v. 430, pp. 476−480, 2004.
- Shaw M.L., McLauchlan J., Mills P.R., Patel A.H., McCruden E.A. // Characterisation of the differences between hepatitis Π‘ virus genotype 3 and 1 glycoproteins // J. Med. Virol., v. 70(3), pp. 361−372, 2003.
- Shimizu Y.K., Igarashi H., Kiyohara Π’., Shapiro M., Wong D.C., Purcell R.H., Yoshikura H. // Infection of a chimpanzee with hepatitis Π‘ virus grown in cell culture // J. Gen. Virol., v.79(Pt6), pp. 1383−1386, 1998.
- Soldaini E., Wack A., D’Oro U., Nuti S., Ulivieri C., Baldari C.T., Abrignani S. // T cell costimulation by the hepatitis Π‘ virus envelope protein E2 binding to CD81 is mediated by Lck // Eur. J. Immunol., v. 33(2), pp. 455−464, 2003.
- Steinkuhler C., Biasiol G., Brunetti M., Urbani A., Koch U., Cortese R., Pessi A., De Francesco R. // Product inhibition of the hepatitis Π‘ virus NS3 protease // Biochemistry., v. 37(25), pp. 8899−8905, 1998.
- Szabo E., Lotz G., Paska C., Kiss A., Schaff Z. // Viral hepatitis: new data on hepatitis Π‘ infection // Pathol. Oncol. Res., v. 9(4), pp. 215−221, 2003.
- Tai C-L., Pan W-C., Liaw S-H., Yang U-C., Hwang L-H., and Chen D-H. // Structure-based mutational analysis of the hepatitis Π‘ virus NS3 helicase // J. of Virology., v. 75(17), pp. 8289−8297, 2001.
- Tanikawa K. // Pathogenesis and treatment of hepatitis Π‘ virus-related liver diseases // Hepatobiliary Pancreat. Dis. Int., v. 3(1), pp. 17−20, 2004.
- Teoh N.C., Farrell G.C. // Management of chronic hepatitis Π‘ virus infection: a new era of disease control // Intern. Med. J., v. 34(6), pp. 32 437, 2004.
- Thimme R., Oldach D., Chang K-M., Steiger C., Ray S.C., and Chisari F.V. // Determinants of viral clearance and persistence during acute hepatitis Π‘ virus infection // J. Exp. Med., v. 184(10), 1395−1406, 2001.
- Torresi J., Bharadwaj M., Jackson D.C., Gowans E.J. // Neutralising antibody, CTL and dendritic cell responses to hepatitis Π‘ virus: a preventative vaccine strategy // Curr. Drug. Targets., v. 5(1), pp. 41−56, 2004.
- Urbani A., Bazzo R., Nardi M.C., Cicero D.O., Francesco R., Steinkuhler C., and Barbato G. // The metal binding site of the hepatitis Π‘ virus NS3 protease//J. of Biol. Chem., v. 273(30), pp. 18 760−18 769, 1998.
- Wisdom G.V. // Peptide Antigens // Oxford University Press Inc., Oxford New York Tokyo., P. 252, 1994.
- Woollard D.J., Grakoui A., Shoukry N.H., Murthy K.K., Campbell K.J., Walker C.M. // Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee // Hepatology., v.38(5), pp. 1297−1306, 2003.
- Wood J., Frederickson R.M., Fields S., and Patel A.H. // Hepatitis Π‘ vims 3'X region interacts with human ribosomal proteins // J. of Virology, v. 75(3), pp. 1348−1358, 2001.
- Wright-Minogue J., Yao N., Zhang R., Butkiewicz N.J., Baroudy B.M., Lau J.Y., Hong Z. // Cross-genotypic interaction between hepatitis Π‘ vims NS3 protease domains and NS4A cofactors // J. Hepatol., v. 32(3), pp. 497 504, 2000.
- Xie Z.C., Riezu-Boj J.I., Lasarte J.J., Guillen J., Su J.H., Civeira M.P., Prieto J. // Transmission of hepatitis Π‘ vims infection to tree shrews // Virology., v. 244(2), pp. 513−520, 1998.
- Xu J., Ye L., Gao J., Zhang Π., Ruan H., Wu Z. // Detection of antibody against hepatitis Π‘ vims first envelope (HCV-E1) protein and its clinical application // Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi., v. 16(4), pp. 392−394, 2002.
- Yao P., ΠΠΈ X., Hu D. // Study of hepatitis Π‘ vims specific immune responses in anti-HCV positive patients without hepatitis Π‘ viremia // Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi., v. 14(3), pp. 22 730, 2000.
- Yi M., Kaneko S., Yu D.Y., Murakami S. // Hepatitis Π‘ virus envelope proteins bind lactoferrin// J. Virol., v. 71(8), pp. 5997−6002, 1997.
- Zhang X.X., Zhang S.Y., Liu J., Lu Z.M., Wang Y. // Expression of hepatitis Π‘ virus hypervariable region 1 and its clinical significance // World J. Gastroenterol., v. 9(5), pp. 1003−1007, 2003.